Henry Ford Hospital Medical Journal


The management of disseminated prostatic carcinoma with hormonal and chemotherapeutic agents is discussed. Hormonal manipulation consists of ablative as well as additive modalities. A new agent, Adriamycin, has shown some effectiveness In selected cases. Significant difficulties are encountered in assessing the objective state of remission of patients undergoing therapy. Further advances through co-operative, randomized clinical trials must be sought. The development of additional chemotherapeutic agents will hopefully expand our horizons.